Home » Johnson & Johnson single-dose COVID vaccine update
General News

Johnson & Johnson single-dose COVID vaccine update



J&J’s vaccine was secure and supplied robust safety in opposition to average to extreme COVID-19, in accordance with preliminary outcomes from a large worldwide research.

BRUNSWICK, N.Y. — Johnson & Johnson requested U.S. regulators Thursday to clear the world’s first single-dose COVID-19 vaccine, an easier-to-use choice that might enhance scarce provides.

J&J’s vaccine was secure and supplied robust safety in opposition to average to extreme COVID-19, in accordance with preliminary outcomes from a large worldwide research.

Editor’s observe: The video above is from a report on Jan. 29 on the preliminary findings of the Johnson & Johnson vaccine.

It didn’t seem fairly as robust as two-dose opponents made by Pfizer and Moderna — a discovering that could be extra notion than actuality, given variations in how every was examined.

However the Meals and Drug Administration is asking its unbiased advisers to publicly debate all the information behind the single-dose shot — similar to its opponents have been put below the microscope — earlier than it decides whether or not to inexperienced gentle a 3rd vaccine choice within the U.S.

Dr. Peter Marks, FDA’s vaccine chief, has cautioned in opposition to making comparisons earlier than the proof is all in.

“With a lot must get this pandemic below management, I feel we are able to’t ignore any device within the device chest,” he instructed the American Medical Affiliation final week. “We should do our greatest to attempt to guarantee that we discover the populations that profit probably the most from every of those vaccines and deploy them in a really considerate method.”

WHAT THE NUMBERS SHOW

Total, the single-dose vaccine was 66% efficient at stopping average to extreme COVID-19, in accordance with early findings from a research of 44,000 folks within the U.S., Latin America and South Africa.

But it surely was 85% protecting in opposition to probably the most critical signs — and beginning 28 days after their shot, researchers discovered nobody who acquired the vaccine wanted hospitalization or died.

WEAKER BUT STILL FIGHTS MUTATING VIRUS

The one-dose choice labored higher within the U.S. — 72% efficient in opposition to average to extreme COVID-19 — in contrast with 66% in Latin America and 57% in South Africa, the place a extra contagious mutant virus is spreading.

Scientists have been in search of real-world proof about how vaccines work because the world races to remain forward of the quickly mutating virus, and welcomed the information that the J&J choice — whereas weaker — did nonetheless provide safety.

OTHER OPTIONS

In giant U.S. research, two doses of the Pfizer and Moderna vaccines proved 95% protecting in opposition to any symptomatic COVID-19.

However these research have been completed earlier than the file virus surges of latest months and the looks of the worrisome mutants, that means such testing may not end up the identical if repeated right this moment.

J&J is also learning a two-dose model of its vaccine, however outcomes received’t be obtainable for a number of extra months.

THE SUPPLY

J&J stated it will have some vaccine able to ship if the FDA permits emergency use of the shot, however it didn’t reveal how a lot. The pharmaceutical big stated it expects to provide 100 million doses to the U.S. by the top of June.

It expects to file the same utility with European regulators quickly.

The Related Press Well being and Science Division receives assist from the Howard Hughes Medical Institute’s Division of Science Training. The AP is solely answerable for all content material.



Supply hyperlink

About the author

admin

Add Comment

Click here to post a comment

Your email address will not be published. Required fields are marked *